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Synthesis of a series of new ketoprofenamides (3a-h) is described. Amide formation was
achieved by aminolysis of ketoprofen benzotriazolide (2) with various amines: primary, sec-
ondary, hydroxylamine and amino acid -alanine. The structures of synthesized compounds
were characterized by means of IR, 1H and 13C NMR spectroscopies and elemental analysis.
The synthesized compounds are potential prodrugs of a well-known NSAID ketoprofen.
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INTRODUCTION
Ketoprofen, 2-(3-benzoylphenyl)propionic acid, a non-
steroidal anti-inflammatory drug (NSAID), was intro-
duced into therapy in 1986 and so far has gained a wide
acceptance. In addition to anti-inflammatory activity,
ketoprofen also possesses analgesic and antipyretic
properties. It is indicated for long-term management of
rheumatoid arthritis and osteoarthritis, for mild to mod-
erate pain and primary dismenorrhea.1
Derivatization of carboxylic acid NSAIDs to their
amide derivatives has been used for various purposes.
Numerous NSAID amides have proved to be useful pro-
drugs. For example, nepafenac, the amide analogue of
amfenac, exhibits enhanced permeation to ocular tissue
followed by rapid bioactivation to active compound in
posterior segments of the eye.2 The prodrug approach is
also useful in reducing gastrointestinal toxicity of NSAIDs,
which is the major side-effect of this class of drugs. Am-
ide derivatives of diclofenac, tolfenamic acid, ibuprofen
and indomethacin with a well known antioxidant cyste-
amine, exhibit good anti-inflammatory and antioxidant
activities and show very significant reduction of ulcero-
genicity.3 Glycine amides of ketoprofen and several other
well known NSAIDs are significantly less irritating to
gastric mucosa, while their anti-inflammatory activities
are comparable to their parent drugs.4,5 Ketoprofen glyci-
nate methyl ester has higher anti-inflammatory and anal-
gesic activity then the parent drug.6 Ketoprofenamides
with heterocyclic residues (2-thiazolinyl, 4-methylpyridyl,
3-hydroxypyridyl, pyridyl, 1,5-dimethyl-2-phenylpyra-
zolonyl or thiazolyl) also possess significant analgesic
and anti-inflammatory activities,7 while ketoprofen 2-hy-
droxyethylamide and ketoprofen esters with bis(hydroxy-
alkylthio)alkanes are useful in the treatment and prevention
of atherosclerosis.8 Some amides possess anti-inflamma-
tory activity independent of the parent compound. Napro-
xen-lysine derivative is at least as active in inhibiting
prostaglandin synthesis as naproxen itself.9 Primary and
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secondary amide derivatives of indomethacin and meclo-
fenamic acid are potent and selective cyclooxygenase-2
inhibitors.10,11 In the indomethacin series, esters and pri-
mary and secondary amides are superior to tertiary ami-
des as selective inhibitors. In the meclofenamic acid and
5,8,11,14-eicosatetraynoic acid series, only the amide de-
rivatives inhibit COX-2, while the esters are either inactive
or nonselective.10 Furthermore, enantiomers of ketoprofen
and some other chiral NSAIDs can be separated through its
diastereomeric amide derivatives by gas,12 column13 or liq-
uid chromatography on chiral stationary phases.14–15
The present paper reports the synthesis and spectro-
scopic characterization of several ketoprofenamides, as
potential NSAID drugs or prodrugs.
RESULTS AND DISCUSSION
In our previous paper, a new and convenient method of
ketoprofen ester preparation via benzotriazolide was re-
ported.16 In this paper, an analogous method is applied
to ketoprofenamides. In the first step, carboxylic group
of ketoprofen reacted with N-1-benzotriazolecarboxylic
acid chloride (1). After decarboxylation, the formed un-
stable mixed anhydride gave ketoprofen benzotriazolide
(2). The benzotriazole activated fenoprofen readily reacted
with various amino compounds (primary and secondary
amines, hydroxylamines and amino acid -alanine) giv-
ing the corresponding amides 3 (Scheme 1).
The following ketoprofenamides were synthesized:
propyl (3a), N,N-diethyl (3b), cyclohexyl (3c), 2-amino-
ethyl (3d), -alanine (3e), 2-hydroxyethyl (3f), 3-hydroxy-
propyl (3g) and N,N-di(2-hydroxyethyl) (3h). All amides,
except amide 3f, are new compounds. Compound 3f was
previously synthesised, but the literature report8 gave no
spectroscopic characterisation. Therefore, its spectroscopic
data are reported here, together with the data for the new
compounds. In addition, our method provides product 3f
in significantly higher yield (88 %), in comparison with
the previously reported method (40.6 %).
The amide preparation proceeded in mild conditions,
at room or even lower temperature. In syntheses of 3a–c
and 3f–h, a five-fold excess of amine was added (Methods
A and D). Even higher excess of amine was used in prepa-
ration of amide 3d (Method B), in order to avoid bis-
product formation. Preparation of amide 3e was performed
with equimolar ratio of benzotriazolide 2 and -alanine,
in the presence of triethylamine, which formed a salt
with by-product benzotriazole and prevented its reaction
with the starting amino compound (Method C). Reactions
with lipophilic amines (propylamine, diethylamine, cyclo-
hexylamine, ethylenediamine) were performed in dry to-
luene, reaction with -alanine in water/acetone mixture
and reactions with hydrophilic bifunctional amines (2-
hydroxyethylamine, 3-hydroxypropylamine and diethanol-
amine) in acetonitrile. To prevent reaction of 2 with hy-
droxyl group, reactions were performed at a lower tem-
perature (10 °C), by addition of the benzotriazolide solu-
tion to the excess of hydroxylamine. Amino group, as a
stronger nucleophile, reacted first and no ester formation
occurred. The reactions with all primary amines and with
diethanolamine were practically instant, while the reac-
tion with diethylamine lasted much longer.
Spectral assignment and CHN analysis of all synthe-
sized compounds confirmed their structures. FTIR spectra
of 3 showed the characteristic absorbtion bands for OH at 
3308–3390 cm–1 (compounds 3f-h),  NH at 3296–3310
cm–1 (all compounds), COOH carbonyl at  1715 cm–1
(3e) and amide group at  1644–1660 cm–1 (amide I) and
 1537–1598 cm–1 (amide II) (all compounds). The stretch-
ing vibration of ketone carbonyl moiety in most cases over-
lapped with amide I carbonyl absorption. The parallel dis-
play of FTIR spectra of ketoprofen, ketoprofen benzotri-
azolide (2) and one of the synthesised amide (3a) is pre-
sented in Figure 1. Reaction conditions, yields, physical,
IR spectroscopic and CHN data of compounds 3a-h are
given in Table I.
13C and 1H NMR chemical shifts of compounds 3a-h
were assigned by the combined use of one- and two-di-
mensional NMR spectra. Proton resonances were deduced
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Figure 1. Parallel display of FTIR spectra of ketoprofen, ketoprofen
benzotriazolide (2) and ketoprofen propylamide (3a).
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from high-resolution 1H and COSY spectra, while those
of carbon from APT, HMQC and HMBC spectra. 13C and
1H NMR chemical shifts are listed in Table II and III, re-
spectively. HMBC NMR spectrum of 3j is shown in Fig-
ure 2. Ketoprofen 2-hydroxyethylamide (3f) was previ-
ously synthesised,8 but the literature report gives no
spectroscopic characterization. Therefore, its spectrosco-
pic data are reported here, together with the data for the
new compounds.
Preliminary hydrolysis studies showed that ketoprofen
could be released from the prepared amides, but detailed
kinetic studies and evaluation of potential pharmaceuti-
cal use still remain to be done.
EXPERIMENTAL
Melting points were determined on a Boëtius Microheating
Stage (Franz Küstner Nachf. KG, Germany) and remained
uncorrected. IR spectra (KBr pellets) were recorded on a
FT-IR Perkin Elmer Paragon 500 spectrometer (Perkin El-
mer, UK).
NMR experiments were carried out on a Bruker Avance
DRX500 spectrometer operating at 500.13 MHz for 1H, with
a 5 mm diameter inverse detection probe and a z-axis gradient
coil. The solvent was DMSO-d6 and all experiments were
performed at ambient temperature. TMS was used as the in-
ternal standard. 1H NMR experiments were performed with
spectral width of 10000 Hz, 65 K data points and 8–16 scans.
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TABLE III. 1H NMR chemical shifts,  in ppm, for ketoprofen and amides 3a-3h, recorded in DMSO-d6 solution
Compd.
H
Ketoprofen 3a 3b 3c 3d 3e 3f 3g 3h
12.5(COOH) 8.04 (NH) 7.93 (NH) 8.05 (NH)
1.65 (NH2)
8.10 (NH) 8.07 (NH)
4.66 (OH)
8.02 (NH)
4.39 (OH)
4.16 (OH)
2 3.82 3.70 4.14 3.69 3.71 3.70 3.74 3.70 4.29
3 1.40 1.35 1.30 1.34 1.36 1.33 1.32 1.35 1.30
4
5 7.68 7.73 7.66 7.73 7.73 7.72 7.73 7.72 7.67
6
7 7.60 7.59 7.60 7.58 7.59 7.56 7.59 7.59 7.59
8 7.52 7.50 7.52 7.50 7.50 7.48 7.50 7.50 7.52
9 7.60 7.63 7.62 7.61 7.62 7.60 7.63 7.62 7.61
1'
2'
3' 7.74 7.73 7.70 7.73 7.73 7.72 7.73 7.73 7.72
4' 7.57 7.57 7.56 7.55 7.57 7.58 7.57 7.57 7.57
5' 7.69 7.69 7.68 7.69 7.69 7.68 7.69 7.69 7.69
6' 7.57 7.57 7.56 7.55 7.57 7.58 7.57 7.57 7.57
7' 7.74 7.73 7.70 7.73 7.73 7.72 7.73 7.73 7.72
1'' 2.99 3.27 3.48 3.613.58 3.153.26 3.09 3.08 3.233.28
3.423.51
2'' 1.36 0.93 1.161.19
1.75
3.283.13 2.26 3.36 1.51 3.303.52
3'' 0.78 3.16
3.35
1.191.25
1.67
3.35 3.163.23
3.433.52
4'' 0.97 1.191.25
1.67
3.303.52
5'' 1.081.14
1.52
6'' 1.011.08
1.60
The sample concentration was 30 mg ml–1. The digital res-
olution was 0.15 Hz per point. In 13C NMR spectra the
spectral width was 31440 Hz, number of data points 65 K
and number of scans 500–1000 per spectrum. The digital
resolution was 0.5 Hz per point. Two-dimensional absolute
value gradient selected COSY spectra were recorded under
the following conditions. Spectral width was 6660 Hz in
both domains, 2 K data points were applied in time domain
and 256 increments were collected for each data set with
linear prediction and zero filling to 1 K. A relaxation delay
was 1.5 s. Spectra were processed with sine window func-
tions. The digital resolution was 3.3 Hz per point in f1 and
26.0 Hz per point in f2 domain. The number of scans was 4.
Absolute value HSQC and HMBC spectra were recorded
with a relaxation delay of 1.5 s and 8-16 scans per incre-
ment. The spectral width was 6600 Hz in acquisition do-
main f2 and 31000 Hz in time domain f1. Data were col-
lected into 2048  256 acquisition matrix and processed us-
ing a 2K  1K transformed matrix with zero filling in f1
domain. Sine multiplication was performed prior to Fourier
transformations. In HMBC spectra the delay for long-range
couplings was set to 60 ms.
For TLC, silica gel plates Kieselgel 60 F254 (Merck,
Germany) and the following solvents and solvent mixtures
were used: ethyl acetate, methanol, cyclohexane/ethyl acetate
(1:1), ethyl acetate/methanol (1:1 and 9:1) and butanol/ace-
tic acid/water (8:1:1). Spots were visualized by short-wave
UV light and iodine vapor. Column chromatography was
performed on silica gel (Kemika, Croatia), 0.063-0.200 mm,
with ethyl acetate, ethyl acetate/methanol (1:1), cyclohex-
ane/ethyl acetate (1:3), dichloromethane/methanol (1:1) as
eluent. Ketoprofen was kindly obtained from Belupo, Croatia.
The amines were distilled and dried prior to use. All sol-
vents were of analytical grade purity and dried.
N-1-Benzotriazole carboxylic acid chloride (BtcCl) (1)
Compound 1 was synthesized from benzotriazole and 20 %
phosgene solution in toluene following the published pro-
cedure.17
Ketoprofen benzotriazolide (Ket-Bt) (2)
Compound 2 was synthesized from ketoprofen and N-1-
benzotriazole carboxylic acid chloride (1) according to the
procedure published previously.16
Ketoprofen amides (3a-h)
Method A (amides 3a-c): The appropriate amine (0.0113 mol)
dissolved in 5 ml toluene was added dropwise to a solution
of 2 (0.817 g, 0.0023 mol) in toluene (10 ml). After 15 min
(3a,3c) or 24 h (3b), reaction mixture was extracted 4 times
with water. The organic layer was dried over anhydrous so-
dium sulfate, filtered and evaporated under reduced pressure
to give the corresponding amide 3. Products 3a and 3c were
analytically pure while 3b was additionally purified by col-
umn chromatography (mobile phase cyclohexane/ethyl ace-
tate 1:3).
Method B (amide 3d): A solution of 2 (0.817 g, 0.0023
mol) in 20 ml toluene was added dropwise to a solution of
2-aminoethylamine (6.760 g, 0.1125 mol) in toluene (50 ml).
After 45 min, reaction mixture was extracted 5 times with
water. Aqueous layers were collected and extracted 5 times
with dichloromethane. Organic extracts were dried over an-
hydrous sodium sulfate and evaporated under reduced pres-
sure to give amide 3d. Crude product was purified by col-
umn chromatography using dichloromethane/methanol 1:1
as a mobile phase.
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Figure 2. HMBC NMR spectrum
of compound 3f.
Method C (amide 3e): To a solution of -alanine (0.205 g,
0.0023 mol) and TEA (0.465 g, 0.0046 mol) in water/acetone
mixture (2 ml + 1 ml), a solution of 2 (0.817 g, 0.0023 mol) in
acetone (7 ml) was added dropwise. The reaction mixture was
stirred for 30 min at room temperature. Acetone was evapo-
rated under reduced pressure. The aqueous solution was acidi-
fied to pH 1 and extracted 3 times with dichloromethane. The
organic layer was dried (Na2SO4), filtered and evaporated un-
der reduced pressure. The analytically pure sample 3e was ob-
tained by column chromatography with ethyl acetate as a mo-
bile phase (elution of benzotriazole) and ethyl acetate/metha-
nol 1:1 mixture (elution of the product).
Method D (amides 3f-h): A solution of 2 (0.817 g, 0.0023
mol) in acetonitrile (10 ml) was added dropwise to a cold
mixture of the appropriate hydroxylamine (0.0113 mol) in
acetonitrile (5 ml). The reaction mixture was stirred for 30–45
min at 10 °C and evaporated under reduced pressure. The
residue was dissolved in dichloromethane and extracted 3
times with water. The organic layer was dried (Na2SO4) and
evaporated under reduced pressure. The analytically pure sam-
ples 3f-h were obtained by triturating with petrolether/cyclo-
hexane 1:1 and column chromatography with ethyl aceta-
te/methanol 1:1 mobile phase, respectively.
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SA@ETAK
Novi amidi ketoprofena: priprava i spektroskopska karakterizacija
Marijana Zovko, Branka Zorc, Milena Jadrijevi}-Mladar Taka~, Biserka Metelko i Predrag Novak
Opisana je priprava novih amida ketoprofena aminolizom benzotriazolida ketoprofena s primarnim i sekun-
darnim aminima, hidroksilaminima i -alaninom. Pripravljeni spojevi karakterizirani su pomo}u IR, 1H i 13C
NMR spektroskopija i elementarne analize, a predstavljaju potencijalne prolijekove nesteroidnoga protuupalnoga
lijeka ketoprofena.
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